Comparing postprandial efficacy in type 2 diabetic patients receiving mitiglinide and sitagliptin by using continuous glucose monitoring: A pilot study

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 17, 2014, Pages 2479-2485

  Ando, Kiyotaka ^a   Nishimura, Rimei ^a,b   Seo, Chiaki ^a   Tsujino, Daisuke ^a   Sakamoto, Masaya ^a   Utsunomiya, Kazunori ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Clinical trial; Continuous glucose monitoring; Mitiglinide; Postprandial glucose; Sitagliptin; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; MITIGLINIDE; SITAGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; ISOINDOLE DERIVATIVE; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; DIABETIC PATIENT; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; POSTPRANDIAL STATE; ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; ISOINDOLES; MIDDLE AGED; PILOT PROJECTS; POSTPRANDIAL PERIOD; PYRAZINES; TRIAZOLES;

EID: 84910091925     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.970531     Document Type: Article

References (25)

1. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999;354:617-21
2. Nakagami T; DECODA Study Group. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004;47:385-94.
3. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-83
4. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose-fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-7
5. 2011 Guideline for Management of PostMeal Glucose in Diabetes 2011. Available from: www.idf.org/sites/default/files/postmeal%20glucose%20guidelines.pdf
6. American Diabetes Association. Standards of medical care in diabetes - 2014. Diabetes Care 2014;37(Suppl):S14-80
7. Reimann F, Proks P, Ashcroft FM. Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel. Br J Pharmacol 2001;132(7):1542-8
8. Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3(3):153-65
9. Edgerton DS, Johnson KM, Cherrington AD. Current strategies for the inhibition of hepatic glucose production in type 2 diabetes. Front Biosci (Landmark Ed) 2009;14:1169-81
10. Sanusi H. The role of incretin on diabetes mellitus. Acta Med Indones 2009;41(4):205-12
11. Esposito K, Giuqliano D, Nappo F, et al. Regression of carotid atherosclerosis by control o postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004;110:214-19
12. Fadini GP, Boscaro E, Albiero M, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal- derived factor-1alpha. Diabetes Care 2010;33(7):1607-9
13. Cheyne EH, Cavan DA, Kerr D. Performance of a continuous glucose monitoring system during controlled hypoglycaemia in healthy volunteers. Diabetes Technol Ther 2002;4:607-13
14. Boyne MS, Silver DM, Kaplan J, et al. Timing of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensor. Diabetes 2003;52:2790-4
15. Service FJ, Molnar GD, Rosevear JW, et al. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970;19(9):644-55
16. SPSS software. Available from: www.spss.com
17. Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 2004;66S:S37-43.
18. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010;12(8):648-58
19. Herman GA, Mistry GC, Yi B, et al. Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inbition following single doses of sitagliptin in healthy, young Japanese males. Br J Clin Pharmacol 2011;71(3):429-36
20. Malaisse WJ. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat Endocrinol 2003;2(6):401-14
21. Available from: http://www.info.pmda.go.jp/downfiles/ph/PDF/230034-3969008F1029-1-14.pdf
22. Polonsky KS, Given BD, Hirsch LJ, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988;318:1231-9
23. Seo C, Sakamoto M, Nishimura R, et al. Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: a continuous glucose monitoring-based pilot study. Diabetes Technol Ther 2013;15(5):378-85
24. Iwamoto Y, Taniguchi T, Nonaka K, et al. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J 2010;57(5):383-94
25. Jung JA, Kaku K, Kim JH, et al. Additive postprandial glucose-lowering effects of mitiglinide and sitagliptin inpatients with type 2 diabetes mellitus. Adv Ther 2013;30(11):1018-29